[1] GIBBONS G H，DZAU V J. The emerging concept

of vascular remodeling[J]. N Engl J Med，1994，330

（20）：1431-1438.

[2] MCGRATH J C，DEIGHAN C，BRIONES A M，

et al. New aspects of vascular remodelling：the

involvement of all vascular cell types[J]. Exp Physiol，

2005，90（4）：469-475.

[3] BRIONES A M，ARRIBAS S M，SALAICES M.

Role of extracellular matrix in vascular remodeling

of hypertension[J]. Curr Opin Nephrol Hypertens，

2010，19（2）：187-194.

[4] INTENGAN H D，SCHIFFRIN E L. Vascular

remodeling in hypertension：roles of apoptosis，

inflammation，and fibrosis[J]. Hypertension，2001，

38（3）：581-587.

[5] BEAVO J A，BRUNTON L L. Cyclic nucleotide

research -- still expanding after half a century[J].

Nat Rev Mol Cell Biol，2002，3（11）：710-718.

[6] KOPPERUD R，KRAKSTAD C，SELHEIM F，et al.

cAMP effector mechanisms. Novel twists for an 'old'

signaling system[J]. FEBS Lett，2003，546（1）：121-

126.

[7] CONTI M，BEAVO J. Biochemistry and physiology

of cyclic nucleotide phosphodiesterases：essential

components in cyclic nucleotide signaling[J]. Annu

Rev Biochem，2007，76（7）：481-511.

[8] LORENOWICZ M J，FERNANDEZ-BORJA

M，HORDIJK P L. cAMP signaling in leukocyte

transendothelial migration[J]. Arterioscler Thromb

Vasc Biol，2007，27（5）：1014-1022.

[9] RABABA'H A，SINGH S，SURYAVANSHI S V，et

al. Compartmentalization role of A-kinase anchoring

proteins （AKAPs） in mediating protein kinase A

（PKA） signaling and cardiomyocyte hypertrophy[J].

Int J Mol Sci，2014，16（1）：218-229.

[10] JEYARAJ SC，UNGER NT，CHOTANI

MA. Rap1 GTPases：an emerging role in the

cardiovasculature[J]. Life Sci，2011，88（15-16）：

645-652.

[11] FANTIDIS P，FERNANDEZ-ORTIZ A，

ARAGONCILLO P，et al. Effect of cAMP on the

function of endothelial cells and fibromuscular

proliferation after the injury of the carotid and

coronary arteries in a porcine model[J]. Rev Esp

Cardiol，2001，54（8）：981-989.

[12] SHAW SK，PERKINS BN，LIM YC，et al. Reduced

expression of junctional adhesion molecule and

platelet/endothelial cell adhesion molecule-1 （CD31）

at human vascular endothelial junctions by cytokines

tumor necrosis factor-alpha plus interferon-gamma

does not reduce leukocyte transmigration under

flow[J]. Am J Pathol，2001，159（6）：2281-2291.

[13] ELENKOV IJ，WILDER RL，CHROUSOS GP，et

al. The sympathetic nerve--an integrative interface

between two super systems：the brain and the

immune system[J]. Pharmacol Rev，2000，52（4）：

595-638.

[14] MATSUMOTO Y，MARUKAWA K，OKUMURA

H，et al. Comparative study of antiplatelet drugs in

vitro：distinct effects of cAMP-elevating drugs and

GPIIb/IIIa antagonists on thrombin-induced platelet

responses[J]. Thromb Res，1999，95（1）：19-29.

[15] KOMAROVA Y，MALIK AB. Regulation of

endothelial permeability via paracellular and

transcellular transport pathways[J]. Annu Rev

Physiol，2010，72（10）：463-493.

[16] PARK TY，BAIK EJ，LEE SH. Prostaglandin

E（2）-induced intercellular adhesion molecule-1

expression is mediated by cAMP/Epac signalling

modules in bEnd. 3 brain endothelial cells[J]. Br J

Pharmacol，2013，169：604-618.

[17] LEHRKE M，KAHLES F，MAKOWSKA A，et al.

PDE4 inhibition reduces neointima formation and

inhibits VCAM-1 expression and histone methylation

in an Epac-dependent manner[J]. J Mol Cell Cardiol，

2015，81（4）：23-33.

[18] PARNELL E，YARWOOD SJ. Interactions between

Epac1 and ezrin in the control of endothelial barrier

function[J]. Biochem Soc Trans，2014，42（2）：274-

278.

[19] SCHLEGEL N，WASCHKE J. cAMP with other

signaling cues converges on Rac1 to stabilize

the endothelial barrier- a signaling pathway

compromised in inflammation[J]. Cell Tissue Res，

2014，355（3）：587-596.

[20] ELFERINK JG，DE KOSTER BM. Inhibition

of interleukin-8-activated human neutrophil

chemotaxis by thapsigargin in a calcium- and cyclic

AMP-dependent way[J]. Biochem Pharmacol，2000，

59（4）：369-375.

[21] VANUFFELEN BE，DE KOSTER BM，ELFERINK

JG. Interaction of cyclic GMP and cyclic AMP

during neutrophil migration：involvement of

phosphodiesterase type III[J]. Biochem Pharmacol，

1998，569（8）：1061-1063.

[22] DONG H，OSMANOVA V，EPSTEIN PM，et al.

Phosphodiesterase 8 （PDE8） regulates chemotaxis

of activated lymphocytes[J]. Biochem Biophys Res

Commun，2006，345（2）：713-719.

[23] LANG P，GESBERT F，DELESPINECARMAGNAT

M，et al. Protein kinase A

phosphorylation of RhoA mediates the morphological

and functional effects of cyclic AMP in cytotoxic

lymphocytes[J]. EMBO J，1996，15（3）：510-519.

[24] PULLAMSETTI SS，SAVAI R，SCHAEFER

MB，et al. cAMP phosphodiesterase inhibitors

increases nitric oxide production by modulating

dimethylarginine dimethylaminohydrolases[J].

Circulation，2011，123（11）：1194-1204.

[25] DZAU VJ，BRAUN-DULLAEUS RC，SEDDING

DG. Vascular proliferation and atherosclerosis：new

perspectives and therapeutic strategies[J]. Nat Med，

2002，8（11）：1249-1256.

[26] LACOLLEY P，REGNAULT V，NICOLETTI A，

et al. The vascular smooth muscle cell in arterial

pathology：a cell that can take on multiple roles[J].

Cardiovasc Res，2012，95（2）：194-204.

[27] MARX SO，TOTARY-JAIN H，MARKS AR.

Vascular smooth muscle cell proliferation in

restenosis[J]. Circ Cardiovasc Interv，2011，4（1）：

104-111.

[28] MAASS PG，AYDIN A，LUFT FC，et al. PDE3A

mutations cause autosomal dominant hypertension

with brachydactyly[J]. Nat Genet，2015，47（6）：

647-653.

[29] BIHL JC，ZHANG C，ZHAO Y，et al. Angiotensin-

（1-7） counteracts the effects of Ang II on vascular

smooth muscle cells，vascular remodeling

and hemorrhagic stroke：Role of the NFsmall

ka，CyrillicB inflammatory pathway[J]. Vascul

Pharmacol，2015，73（10）：115-123.

[30] GUSAN S，ANAND-SRIVASTAVA MB. cAMP

attenuates the enhanced expression of Gi proteins

and hyperproliferation of vascular smooth muscle cells from SHR：role of ROS and ROS-mediated

signaling[J]. Am J Physiol Cell Physiol，2013，304：

C1198-C1209.

[31] KIMURA T E，DUGGIRALA A，HINDMARCH C

C，et al. Inhibition of Egr1 expression underlies the

anti-mitogenic effects of cAMP in vascular smooth

muscle cells[J]. J Mol Cell Cardiol，2014，72（7）：

9-19.

[32] SEIJI K，TSUDA M，MATSUHASHI T，et al.

Treatment of in-stent restenosis with beraprost

sodium：an experimental study of short- and

intermediate-term effects in dogs[J]. Clin Exp

Pharmacol Physiol，2009，36（12）：1164-1169.

[33] HARADA M，TOKI Y，NUMAGUCHI Y，et

al. Prostacyclin synthase gene transfer inhibits

neointimal formation in rat balloon-injured arteries

without bleeding complications[J]. Cardiovasc Res，

1999，43（2）：481-491.

[34] MCKEAN J S，MURRAY F，GIBSON G，et al. The

cAMP-producing agonist beraprost inhibits human

vascular smooth muscle cell migration via exchange

protein directly activated by cAMP[J]. Cardiovasc

Res，2015，107（9）：546-555.

[35] CAI Y，MILLER C L，NAGEL D J，et al. Cyclic

nucleotide phosphodiesterase 1 regulates lysosomedependent

type I collagen protein degradation

in vascular smooth muscle cells[J]. Arterioscler

Thromb Vasc Biol，2011，31（3）：616-623.

[36] SMOLENSKI A. Novel roles of cAMP/cGMPdependent

signaling in platelets[J]. J Thromb

Haemost，2012，10（2）：167-176.

[37] RASLAN Z，ABURIMA A，NASEEM K M. The

spatiotemporal regulation of cAMP signaling in

blood platelets-old friends and new players[J]. Front

Pharmacol，2015，6（11）：266.

[38] GACHET C. P2Y（12） receptors in platelets and

other hematopoietic and non-hematopoietic cells[J].

Purinergic Signal，2012，8（3）：609-619.

[39] ZHANG W，COLMAN R W. Thrombin regulates

intracellular cyclic AMP concentration in human

platelets through phosphorylation/activation of

phosphodiesterase 3A[J]. Blood，2007，110（10）：

1475-1482.

[40] ROBERTS W，MAGWENZI S，ABURIMA A，et

al. Thrombospondin-1 induces platelet activation

through CD36-dependent inhibition of the cAMP/

protein kinase A signaling cascade[J]. Blood，2010，

116（20）：4297-4306.

[41] WOULFE D S. Platelet G protein-coupled receptors

in hemostasis and thrombosis[J]. J Thromb Haemost，

2005，3（10）：2193-2200.

[42] OFFERMANNS S. Activation of platelet function

through G protein-coupled receptors[J]. Circ Res，

2006，99（12）：1293-1304.

[43] VAN GEET C，IZZI B，LABARQUE V，et al.

Human platelet pathology related to defects in the

G-protein signaling cascade[J]. J Thromb Haemost，

2009，7（Suppl 1）：282-286.